Related Experiment Video

Updated: Jan 7, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

869

Obesity in Cardiorenal syndrome: Management Opportunities and Challenges

Allison Reaves1, Emily Jaffe2, Wendy McCallum3

  • 1Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA, 02111, USA.

Current Hypertension Reports
|December 27, 2025
PubMed

Insights

Obesity, heart failure with preserved ejection fraction, and chronic kidney disease (CKD) are linked. New obesity treatments show cardiovascular and kidney benefits, improving outcomes for these complex conditions.

Area of Science:

  • Cardiology
  • Nephrology
  • Endocrinology

Background:

  • Global obesity prevalence is rising, increasing the risk of cardiovascular disease and chronic kidney disease (CKD).
  • Obesity, heart failure with preserved ejection fraction (HFpEF), and CKD share complex pathophysiological links, including cardiorenal syndrome.
  • Adipocytes contribute to renal sodium retention and volume overload, key factors in cardiorenal syndrome.

Purpose of the Study:

  • To review diagnostic and management strategies for co-existent obesity, HFpEF, and CKD.
  • To examine the impact of obesity treatments on long-term health outcomes in patients with these conditions.

Main Methods:

  • Review of current literature on the interplay between obesity, HFpEF, and CKD.
  • Analysis of evidence regarding the efficacy of emerging obesity treatments.

Main Results:

  • Emerging evidence links obesity, HFpEF, and CKD pathophysiology via adipocyte-mediated renal effects.
  • Glucagon-like peptide-1 receptor agonists demonstrate cardiovascular and kidney benefits in patients with obesity and comorbidities like diabetes, CKD, and HFpEF.
  • Effective obesity management is crucial for improving outcomes in patients with comorbid HFpEF and CKD.

Conclusions:

  • Integrated, multidisciplinary management and shared decision-making are essential for optimizing patient care.
  • Improved recognition and treatment of obesity are key to managing cardiorenal syndromes.
  • Novel obesity pharmacotherapies offer significant benefits for cardiovascular and renal health.
Abstract

Keywords:
Cardiorenal syndromeGlucagon-like peptide-1 receptor agonistsObesity

More Related Videos

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.8K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K

Related Concept Videos

Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
287
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
289
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
153
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
319
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
218